BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2024 7:56:29 AM | Browse: 379 | Download: 1397
 |
Received |
|
2023-11-01 10:51 |
|
Peer-Review Started |
|
2023-11-01 10:52 |
|
First Decision by Editorial Office Director |
|
2023-12-04 19:23 |
|
Return for Revision |
|
2023-12-04 19:23 |
|
Revised |
|
2023-12-11 09:23 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-08 03:09 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-08 08:13 |
|
Articles in Press |
|
2024-01-08 08:13 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-20 15:00 |
|
Publish the Manuscript Online |
|
2024-01-26 07:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Zhe Cao, Guang-Lei Zheng, Tian-Qi Zhang, Hong-Yan Shao, Jia-Yu Pan, Zi-Lin Huang and Meng-Xuan Zuo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Guangdong Province |
2020A1515011539 |
|
| Corresponding Author |
Meng-Xuan Zuo, MD, Attending Doctor, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Yuexiu District, Guangzhou 510060, Guangdong Province, China. zuomx@sysucc.org.cn |
| Key Words |
Unresectable hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Angiogenesis inhibitors; Programmed cell death protein 1; Programmed death ligand 1 |
| Core Tip |
The network meta-analysis showed the treatment based on hepatic arterial infusion chemotherapy (HAIC) had the best efficacy on unresectable hepatocellular carcinoma (uHCC). The retrospective, relatively large-scale study suggested HAIC combined with angiogenesis inhibitors and programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blockers could improve the uHCC patients’ prognosis. After propensity score matching, it demonstrated that triple therapy was able to prolong the uHCC patients’ survival than angiogenesis inhibitors and PD-1/PD-L1 blockers. |
| Publish Date |
2024-01-26 07:56 |
| Citation |
Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i4/318.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i4.318 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
